论文部分内容阅读
目的探讨CLN3(青少年神经元腊样质脂褐质沉积症Juvenile,form of neuronalceroid-lipofuscinosis,JNCL,Batten病)基因在卵巢浆液性囊腺癌中的表达特点及其在卵巢癌化疗耐药中的作用。方法采用半定量RT-PCR、Western blot以及免疫组化的方法检测CLN3在卵巢浆液性囊腺癌中的表达,分析其表达与临床病理特征及化疗耐药的相关性。结果 CLN3在卵巢浆液性囊腺癌中的表达高于正常卵巢组织,且临床分期越晚其表达越高(P<0.05),而与肿瘤患者年龄无显著相关性。CLN3在卵巢癌化疗耐药组表达阳性率明显高于化疗敏感组(P<0.05)。结论卵巢癌中CLN3高表达与卵巢癌的发生、发展、浸润和转移有关,与卵巢癌化疗耐药密切相关。CLN3可成为卵巢癌化疗新的基因治疗靶点。
Objective To investigate the expression of CLN3 (Juvenile, form of neuronalcell-lipofuscinosis, JNCL, Batten disease) in ovarian serous cystadenocarcinoma and its clinical significance in chemoresistance of ovarian cancer effect. Methods The expression of CLN3 in ovarian serous cystadenocarcinoma was detected by semi-quantitative RT-PCR, Western blot and immunohistochemistry. The correlation between the expression of CLN3 and clinicopathological features and chemoresistance was analyzed. Results The expression of CLN3 in ovarian serous cystadenocarcinoma was higher than that in normal ovarian tissue. The higher the clinical stage was, the higher the CLN3 expression was (P <0.05), but no significant correlation with the age of tumor patients. The positive rate of CLN3 expression in chemotherapy-resistant ovarian cancer group was significantly higher than that in chemosensitive group (P <0.05). Conclusion The high expression of CLN3 in ovarian cancer is associated with the occurrence, development, invasion and metastasis of ovarian cancer, which is closely related to the chemoresistance of ovarian cancer. CLN3 can be a new gene therapy target for ovarian cancer chemotherapy.